Momelotinib clinical trials
Also written CYT387 and GS-0387.
How each study uses momelotinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the momelotinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 15 Sept 2023 · OJJAARA · NDA 216873 (FDA, Drugs@FDA)
- European Union
- 25 Jan 2024 · Omjjara · EMEA/H/C/005768 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
21 studies that test it; most in 2014 (6)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 6 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 17 · Other 4
Sierra Oncology LLC - a GSK company (13) · GlaxoSmithKline (4) · SWOG Cancer Research Network (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
Often tested with
Tested in the same studies.
Ruxolitinib (1) · Luspatercept (1) · Gilteritinib (1) · Capecitabine (1)
Related medicines
As reviewed, each with the page that says it.
- One of JAK inhibitors source
- One of Protein Kinase Inhibitors source
- One of Tyrosine kinase inhibitors (TKIs) source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test momelotinib.
- Dec 2026Extended Access of Momelotinib in Adults With MyelofibrosisPhase 2 · GlaxoSmithKline
- Mar 2027Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisPhase 2 · GlaxoSmithKline
- Jul 2027A Study of Momelotinib in Participants With Low-risk Myelodysplastic SyndromePhase 2 · GlaxoSmithKline
- Oct 2027A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid LeukemiaPhase 1/2 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses momelotinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 21
- Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisRecruitingPhase 2GlaxoSmithKlineNCT06517875Written as Momelotinib
- A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid LeukemiaRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06235801Written as Momelotinib
- Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell CountsNot yet recruitingPhase 4SWOG Cancer Research NetworkNCT07498205Written as Momelotinib
- A Study of Momelotinib in Participants With Low-risk Myelodysplastic SyndromeRecruitingPhase 2GlaxoSmithKlineNCT06847867Written as Momelotinib
- A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) SyndromeNot yet recruitingPhase 2/3GlaxoSmithKlineNCT07569081Written as Momelotinib
- Momelotinib During and After HCT in MyelofibrosisRecruitingPhase 1Massachusetts General HospitalNCT07104799Written as Momelotinib
- Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic LeukemiaRecruitingEarly Phase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07071155Written as Momelotinib
- Extended Access of Momelotinib in Adults With MyelofibrosisActive, not recruitingPhase 2GlaxoSmithKlineNCT03441113Written as Momelotinib
- A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)CompletedPhase 3Sierra Oncology LLC - a GSK companyNCT04173494Written as Momelotinib
- Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal AdenocarcinomaTerminatedPhase 3Sierra Oncology LLC - a GSK companyNCT02101021Written as Momelotinib
- Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential ThrombocythemiaCompletedPhase 2Sierra Oncology LLC - a GSK companyNCT02124746Written as Momelotinib
- Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)CompletedPhase 2Sierra Oncology LLC - a GSK companyNCT02515630Written as MMB
- Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MFCompletedPhase 3Sierra Oncology LLC - a GSK companyNCT02101268Written as Momelotinib
- Momelotinib Versus Ruxolitinib in Subjects With MyelofibrosisCompletedPhase 3Sierra Oncology LLC - a GSK companyNCT01969838Written as Momelotinib
- Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential ThrombocythemiaTerminatedPhase 2Sierra Oncology LLC - a GSK companyNCT01998828Written as Momelotinib
- Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia MyelofibrosisCompletedPhase 1/2Sierra Oncology LLC - a GSK companyNCT01423058Written as Momelotinib
- Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)CompletedPhase 2Sierra Oncology LLC - a GSK companyNCT01236638Written as Momelotinib
- Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)CompletedPhase 1/2Sierra Oncology LLC - a GSK companyNCT00935987Written as CYT387
- Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal AdenocarcinomaTerminatedPhase 1Sierra Oncology LLC - a GSK companyNCT02244489Written as Momelotinib (MMB)
- Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)TerminatedPhase 1Sierra Oncology LLC - a GSK companyNCT02206763Written as Momelotinib (MMB)
See all 21 studies that test momelotinib →
Given beside what is tested · 4 — momelotinib is usual care or a partner of the new treatment
- A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative NeoplasmsRecruitingPhase 1Janssen Research & Development, LLCNCT06150157Written as Momelotinib
- A Study of Oral Nuvisertib (TP-3654) in Patients With MyelofibrosisRecruitingPhase 1/2Sumitomo Pharma America, Inc.NCT04176198Written as Momelotinib
- Revumenib in Patients With MyelofibrosisNot yet recruitingPhase 1/2John MascarenhasNCT07734077Written as Momelotinib
- A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaRecruitingPhase 2Karyopharm Therapeutics IncNCT05980806Written as Momelotinib
Codes
What other systems call momelotinib · ClinicalTrials.gg INT005548
- MeSH (NLM) C546012momelotinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 6O01GMS00PMOMELOTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q252602momelotinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C88311MomelotinibOne source FDA
- DrugBank DB11763One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C546012 | momelotinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 6O01GMS00P | MOMELOTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q252602 | momelotinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C88311 | Momelotinib | One source FDA |
| DrugBank | DB11763 | — | One source Wikidata |
Also registered as momelotinib dihydrochloride (UNII RBH995N496) and momelotinib dihydrochloride monohydrate (UNII LDX8893L5D).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.